Skip to main content

Lineage Cell Therapeutics, Inc.

LCTX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000876343

In the last 90 days, Lineage Cell Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 143 institutions reported holding it in 13F filings for Q3 2026, worth $112.0M in total; no superinvestor holds it.

Holders of 5% or more of LCTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lineage Cell Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of LCTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Broadwood Partners, L.P.13D/A23.10%57.8M shares−1.40 ppfrom 24.50%Mar 16, 20216 filingsNov 14, 2025SEC
BlackRock, Inc.13G5.30%13.2M shares+4.30 ppfrom 1.00%Oct 22, 20246 filingsJul 29, 2026SEC
Chernett Jorey13G5.00%11.4M sharesNewSep 26, 20251 filingSep 26, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

15 Schedule 13D and 13G filings on Lineage Cell Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LCTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jul 29, 20263:19 PM ETBlackRock, Inc.13G5.30%13.2M shares+4.30 ppfrom 1.00%Jun 30, 2026SEC
Nov 14, 20256:12 PM ETBroadwood Partners, L.P.and 2 others13D/A23.10%57.8M shares−1.40 ppfrom 24.50%Nov 12, 2025SEC
Sep 26, 202511:52 AM ETChernett Jorey13G5.00%11.4M sharesNewSep 22, 2025SEC
Jul 17, 20257:54 PM ETBlackRock, Inc.13G/A1.00%2.23M shares−4.00 ppfrom 5.00%Below 5%Jun 30, 2025SEC
Apr 24, 20258:48 AM ETBlackRock, Inc.13G5.00%11.5M shares+0.40 ppfrom 4.60%Mar 31, 2025SEC
Feb 5, 20255:28 PM ETBlackRock, Inc.13G/A4.60%10.1M shares–Below 5%Dec 31, 2024SEC
Jan 28, 20258:07 PM ETBroadwood Partners, L.P.and 2 others13D/A24.50%57.8M shares–Jan 27, 2025SEC
Nov 21, 2024Broadwood Partners, L.P.13D/AOld format–––SEC
Nov 8, 2024BlackRock, Inc.13GOld format–––SEC
Oct 22, 2024BlackRock, Inc.13GOld format–New–SEC
Feb 8, 2024Broadwood Partners, L.P.13D/AOld format–––SEC
Jul 8, 20224:57 PM ETBlackRock Inc.13GOld format–––SEC
Mar 25, 2022Broadwood Partners, L.P.13D/AOld format–––SEC
Feb 4, 20224:12 PM ETBlackRock Inc.13GOld format–New–SEC
Mar 16, 2021Broadwood Partners, L.P.13D/AOld format–––SEC

Form 144: proposed insider sales

2 notices from officers, directors and other affiliates planning to sell Lineage Cell Therapeutics, Inc. shares, newest first.

Form 144 notices for LCTX
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Sep 24, 20254:39 PM ETDon M BaileyDirector60.0K$96.0KSep 24, 2025Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Sep 10, 20255:31 PM ETDon M BaileyDirector80.0K$97.5KSep 10, 2025Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC